nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—CHRND—pericardium—esophageal cancer	0.463	0.873	CbGeAlD
Cisatracurium Besylate—Generalised erythema—Cisplatin—esophageal cancer	0.163	0.346	CcSEcCtD
Cisatracurium Besylate—CHRND—lung—esophageal cancer	0.0468	0.0883	CbGeAlD
Cisatracurium Besylate—Hypoxemia—Methotrexate—esophageal cancer	0.037	0.0789	CcSEcCtD
Cisatracurium Besylate—CHRNB1—lymph node—esophageal cancer	0.0206	0.0389	CbGeAlD
Cisatracurium Besylate—Azotaemia—Methotrexate—esophageal cancer	0.014	0.0297	CcSEcCtD
Cisatracurium Besylate—Wheezing—Cisplatin—esophageal cancer	0.0132	0.028	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Methotrexate—esophageal cancer	0.0117	0.0249	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.0102	0.0216	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Cisplatin—esophageal cancer	0.00693	0.0147	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Capecitabine—esophageal cancer	0.00689	0.0147	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Cisplatin—esophageal cancer	0.00669	0.0142	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Capecitabine—esophageal cancer	0.00639	0.0136	CcSEcCtD
Cisatracurium Besylate—Flushing—Cisplatin—esophageal cancer	0.00631	0.0134	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Capecitabine—esophageal cancer	0.00616	0.0131	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Cisplatin—esophageal cancer	0.00615	0.0131	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Cisplatin—esophageal cancer	0.00613	0.0131	CcSEcCtD
Cisatracurium Besylate—Erythema—Cisplatin—esophageal cancer	0.00592	0.0126	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00558	0.0119	CcSEcCtD
Cisatracurium Besylate—Convulsion—Cisplatin—esophageal cancer	0.00513	0.0109	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Capecitabine—esophageal cancer	0.00511	0.0109	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00501	0.0107	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Capecitabine—esophageal cancer	0.00493	0.0105	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Cisplatin—esophageal cancer	0.00483	0.0103	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Cisplatin—esophageal cancer	0.00474	0.0101	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Cisplatin—esophageal cancer	0.00472	0.01	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Cisplatin—esophageal cancer	0.0047	0.01	CcSEcCtD
Cisatracurium Besylate—Flushing—Capecitabine—esophageal cancer	0.00465	0.00991	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Capecitabine—esophageal cancer	0.00455	0.00969	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Capecitabine—esophageal cancer	0.00453	0.00964	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Capecitabine—esophageal cancer	0.00452	0.00962	CcSEcCtD
Cisatracurium Besylate—Hypotension—Cisplatin—esophageal cancer	0.00452	0.00962	CcSEcCtD
Cisatracurium Besylate—Erythema—Capecitabine—esophageal cancer	0.00437	0.00929	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Cisplatin—esophageal cancer	0.00431	0.00917	CcSEcCtD
Cisatracurium Besylate—Hypertension—Capecitabine—esophageal cancer	0.00377	0.00802	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00369	0.00786	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Cisplatin—esophageal cancer	0.00356	0.00758	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Capecitabine—esophageal cancer	0.00349	0.00744	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Capecitabine—esophageal cancer	0.00348	0.0074	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Capecitabine—esophageal cancer	0.00346	0.00737	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Methotrexate—esophageal cancer	0.00339	0.00721	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Methotrexate—esophageal cancer	0.00337	0.00718	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Methotrexate—esophageal cancer	0.00336	0.00716	CcSEcCtD
Cisatracurium Besylate—Hypotension—Capecitabine—esophageal cancer	0.00333	0.00709	CcSEcCtD
Cisatracurium Besylate—Erythema—Methotrexate—esophageal cancer	0.00325	0.00692	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Capecitabine—esophageal cancer	0.00318	0.00676	CcSEcCtD
Cisatracurium Besylate—Rash—Cisplatin—esophageal cancer	0.00305	0.00649	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Cisplatin—esophageal cancer	0.00305	0.00648	CcSEcCtD
Cisatracurium Besylate—Urticaria—Capecitabine—esophageal cancer	0.00283	0.00603	CcSEcCtD
Cisatracurium Besylate—Convulsion—Methotrexate—esophageal cancer	0.00282	0.00599	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00275	0.00585	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Methotrexate—esophageal cancer	0.00265	0.00565	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Capecitabine—esophageal cancer	0.00263	0.00559	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Methotrexate—esophageal cancer	0.0026	0.00554	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Methotrexate—esophageal cancer	0.00258	0.00548	CcSEcCtD
Cisatracurium Besylate—Pruritus—Capecitabine—esophageal cancer	0.00252	0.00537	CcSEcCtD
Cisatracurium Besylate—Hypotension—Methotrexate—esophageal cancer	0.00248	0.00528	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Methotrexate—esophageal cancer	0.00236	0.00503	CcSEcCtD
Cisatracurium Besylate—Rash—Capecitabine—esophageal cancer	0.00225	0.00478	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Capecitabine—esophageal cancer	0.00224	0.00478	CcSEcCtD
Cisatracurium Besylate—Urticaria—Methotrexate—esophageal cancer	0.00211	0.00449	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Methotrexate—esophageal cancer	0.00195	0.00416	CcSEcCtD
Cisatracurium Besylate—Pruritus—Methotrexate—esophageal cancer	0.00188	0.004	CcSEcCtD
Cisatracurium Besylate—Rash—Methotrexate—esophageal cancer	0.00167	0.00356	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Methotrexate—esophageal cancer	0.00167	0.00356	CcSEcCtD
